Literature DB >> 22619239

Executive summary: 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections.

Benjamin A Lipsky1, Anthony R Berendt, Paul B Cornia, James C Pile, Edgar J G Peters, David G Armstrong, H Gunner Deery, John M Embil, Warren S Joseph, Adolf W Karchmer, Michael S Pinzur, Eric Senneville.   

Abstract

Foot infections are a common and serious problem in persons with diabetes. Diabetic foot infections (DFIs) typically begin in a wound, most often a neuropathic ulceration. While all wounds are colonized with microorganisms, the presence of infection is defined by ≥2 classic findings of inflammation or purulence. Infections are then classified into mild (superficial and limited in size and depth), moderate (deeper or more extensive), or severe (accompanied by systemic signs or metabolic perturbations). This classification system, along with a vascular assessment, helps determine which patients should be hospitalized, which may require special imaging procedures or surgical interventions, and which will require amputation. Most DFIs are polymicrobial, with aerobic gram-positive cocci (GPC), and especially staphylococci, the most common causative organisms. Aerobic gram-negative bacilli are frequently copathogens in infections that are chronic or follow antibiotic treatment, and obligate anaerobes may be copathogens in ischemic or necrotic wounds. Wounds without evidence of soft tissue or bone infection do not require antibiotic therapy. For infected wounds, obtain a post-debridement specimen (preferably of tissue) for aerobic and anaerobic culture. Empiric antibiotic therapy can be narrowly targeted at GPC in many acutely infected patients, but those at risk for infection with antibiotic-resistant organisms or with chronic, previously treated, or severe infections usually require broader spectrum regimens. Imaging is helpful in most DFIs; plain radiographs may be sufficient, but magnetic resonance imaging is far more sensitive and specific. Osteomyelitis occurs in many diabetic patients with a foot wound and can be difficult to diagnose (optimally defined by bone culture and histology) and treat (often requiring surgical debridement or resection, and/or prolonged antibiotic therapy). Most DFIs require some surgical intervention, ranging from minor (debridement) to major (resection, amputation). Wounds must also be properly dressed and off-loaded of pressure, and patients need regular follow-up. An ischemic foot may require revascularization, and some nonresponding patients may benefit from selected adjunctive measures. Employing multidisciplinary foot teams improves outcomes. Clinicians and healthcare organizations should attempt to monitor, and thereby improve, their outcomes and processes in caring for DFIs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22619239     DOI: 10.1093/cid/cis460

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  27 in total

1.  Telehealth-guided home-based maggot debridement therapy for chronic complex wounds: Peri- and post-pandemic potential.

Authors:  David G Armstrong; Vincent L Rowe; Karen D'Huyvetter; Ronald A Sherman
Journal:  Int Wound J       Date:  2020-06-18       Impact factor: 3.315

2.  Trends in the epidemiology of osteomyelitis: a population-based study, 1969 to 2009.

Authors:  Hilal Maradit Kremers; Macaulay E Nwojo; Jeanine E Ransom; Christina M Wood-Wentz; L Joseph Melton; Paul M Huddleston
Journal:  J Bone Joint Surg Am       Date:  2015-05-20       Impact factor: 5.284

Review 3.  The Wound Microbiome: Modern Approaches to Examining the Role of Microorganisms in Impaired Chronic Wound Healing.

Authors:  Ana M Misic; Sue E Gardner; Elizabeth A Grice
Journal:  Adv Wound Care (New Rochelle)       Date:  2014-07-01       Impact factor: 4.730

4.  Strain- and Species-Level Variation in the Microbiome of Diabetic Wounds Is Associated with Clinical Outcomes and Therapeutic Efficacy.

Authors:  Lindsay R Kalan; Jacquelyn S Meisel; Michael A Loesche; Joseph Horwinski; Ioana Soaita; Xiaoxuan Chen; Aayushi Uberoi; Sue E Gardner; Elizabeth A Grice
Journal:  Cell Host Microbe       Date:  2019-04-18       Impact factor: 21.023

5.  Risk factors for amputation in patients with diabetic foot infection: a prospective study.

Authors:  Serhat Uysal; Bilgin Arda; Meltem I Taşbakan; Şevki Çetinkalp; Ilgın Y Şimşir; Anıl M Öztürk; Ayşe Uysal; İlgen Ertam
Journal:  Int Wound J       Date:  2017-07-19       Impact factor: 3.315

6.  The silent overall burden of foot disease in a representative hospitalised population.

Authors:  Peter A Lazzarini; Sheree E Hurn; Suzanne S Kuys; Maarten C Kamp; Vanessa Ng; Courtney Thomas; Scott Jen; Jude Wills; Ewan M Kinnear; Michael C d'Emden; Lloyd F Reed
Journal:  Int Wound J       Date:  2016-10-03       Impact factor: 3.315

Review 7.  Recent trends in molecular diagnostics of yeast infections: from PCR to NGS.

Authors:  Toni Gabaldón
Journal:  FEMS Microbiol Rev       Date:  2019-09-01       Impact factor: 16.408

8.  Species-Specific Immunoassay Aids Identification of Pathogen and Tracks Infectivity in Foot Infection.

Authors:  Stephanie P Hao; Elysia A Masters; Mark J Ninomiya; Christopher A Beck; Edward M Schwarz; John L Daiss; Irvin Oh
Journal:  Foot Ankle Int       Date:  2020-11-09       Impact factor: 2.827

9.  Low but Increasing Prevalence of Reduced Beta-lactam Susceptibility Among Invasive Group B Streptococcal Isolates, US Population-Based Surveillance, 1998-2018.

Authors:  Miwako Kobayashi; Lesley McGee; Sopio Chochua; Mirasol Apostol; Nisha B Alden; Monica M Farley; Lee H Harrison; Ruth Lynfield; Paula Snippes Vagnone; Chad Smelser; Alison Muse; Ann R Thomas; Li Deng; Benjamin J Metcalf; Bernard W Beall; Stephanie J Schrag
Journal:  Open Forum Infect Dis       Date:  2020-12-21       Impact factor: 3.835

10.  Evaluation of the appropriate use of commonly prescribed fluoroquinolones and the risk of dysglycemia.

Authors:  Wissam K Kabbara; Wijdan H Ramadan; Peggy Rahbany; Souhaila Al-Natour
Journal:  Ther Clin Risk Manag       Date:  2015-04-22       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.